ABCC2 and ovarian carcinoma: MRP2 inhibition was evaluated by the determination of the uptake amount of the fluorescent 5-carboxy fluorescein diacetate (5-CFDA) substrate, by A2780/RCIS ovarian carcinoma cells overexpressing MRP2 in the presence of the selected compounds.